Scotiabank initiated coverage of Sage Therapeutics with an Outperform rating and $61 price target. The analyst believes the company’s approach toward drug development related to neurosteroid biology could bring novel classes of compounds to disease markets in need of innovative alternatives. In addition, pipeline success could make Sage an attractive acquisition target, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SAGE: